Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Services
SectorN/A
SymbolNASDAQ:BRLI
CUSIP09057G60
Phone+1-201-7912186
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins4.67%
Return on Equity12.67%
Return on Assets8.38%
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Bio-Reference Laboratories (NASDAQ:BRLI) Frequently Asked Questions
What is Bio-Reference Laboratories' stock symbol?
Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."
How were Bio-Reference Laboratories' earnings last quarter?
Bio-Reference Laboratories Inc (NASDAQ:BRLI) posted its quarterly earnings results on Thursday, December, 18th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.63 by $0.03. The medical research company earned $227.60 million during the quarter, compared to analysts' expectations of $228.81 million. Bio-Reference Laboratories had a return on equity of 12.67% and a net margin of 4.67%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.40 EPS. View Bio-Reference Laboratories' Earnings History.
Has Bio-Reference Laboratories been receiving favorable news coverage?
Media coverage about BRLI stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Reference Laboratories earned a news sentiment score of 0.07 on Accern's scale. They also gave news coverage about the medical research company an impact score of 45.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Bio-Reference Laboratories?
Shares of BRLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Bio-Reference Laboratories?
Bio-Reference Laboratories' mailing address is 481 Edward H Ross Dr, ELMWOOD PARK, NJ 07407-3118, United States. The medical research company can be reached via phone at +1-201-7912186.
MarketBeat Community Rating for Bio-Reference Laboratories (BRLI)
MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe BRLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
